Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCLERITA phase II trial of itacitinib in diffuse systemic sclerosis
2019-003430-16Phase 2Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing Itacitinib arm with Placebo arm (2 arms). Primary endpoint: Change in modified Rodnan skin score at 360 days. Started Jun 2020; status: active.
02
Drugs
itacitinib
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2019-003430-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003430-16.